TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies.

@article{Macfarlane2005TRAILRM,
  title={TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies.},
  author={Marion Macfarlane and Susan L Kohlhaas and Michael J. Sutcliffe and Martin J S Dyer and Gerald M. Cohen},
  journal={Cancer research},
  year={2005},
  volume={65 24},
  pages={11265-70}
}
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its agonistic antibodies, which are currently in early clinical trials for treating various malignancies, induce apoptosis through triggering of either TRAIL-R1 or TRAIL-R2. Based on studies using agonistic monoclonal antibodies, we recently proposed that primary chronic lymphocytic leukemic cells seem to signal apoptosis primarily through TRAIL-R1. We have now synthesized mutant forms of TRAIL specific for TRAIL-R1 or TRAIL-R2… CONTINUE READING
76 Citations
20 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 76 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 20 references

Similar Papers

Loading similar papers…